Skip to main content
Clinical Trials/EUCTR2018-002176-41-DE
EUCTR2018-002176-41-DE
Active, not recruiting
Phase 1

PREvention of STroke in Intracerebral haemorrhaGE survivors with Atrial Fibrillation (PRESTIGE-AF)

Imperial College of Science Technology and Medicine0 sites654 target enrollmentMarch 18, 2019

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Ischaemic stroke prevention in patients with atrial fibrillation and previous intracerebral haemorrhage
Sponsor
Imperial College of Science Technology and Medicine
Enrollment
654
Status
Active, not recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 18, 2019
End Date
TBD
Last Updated
last year
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\. Age \= 18 years
  • 2\. Written informed consent from the patient or legal representative
  • 3\. Recent history of a non\-traumatic spontaneous ICH during the 12 months before enrolment
  • 4\. Documented evidence of AF (paroxysmal, persistent or permanent)
  • CHA2DS2\-VASc score\=2 for male, and CHA2DS2\-VASc score\= 3 for female patients
  • 5\. Availability of brain imaging following the index Intracerebral Haemorrhage (ICH)
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range 100

Exclusion Criteria

  • 1\. Fully dependent (defined as a modified Rankin Scale score of over 4\)
  • 2\. Women who are pregnant, breastfeeding, or plan to become pregnant during the Study period
  • 3\. Women of childbearing potential (WOCBP) who are unable or unwilling to take measures for effective contraception
  • 4\. ICH occurring within the last 14 days before enrolment
  • 5\. ICH occurring longer than 12 months before enrolment
  • 6\. ICH resulting from trauma or vascular malformation
  • 7\. Another indication for long\-term anticoagulation
  • 8\. Contraindication for long\-term anticoagulant therapy with DOACs (other than ICH)
  • 9\. Absolute need for antiplatelet therapy at enrolment
  • 10\. Presence of a left atrial appendage occlusion device (LAAO) or plan to implant an LAAO

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
Prevention of Stroke in Survivors of Brain Bleeding with Atrial Fibrillatio
EUCTR2018-002176-41-ATImperial College of Science, Technology and Medicine654
Active, not recruiting
Phase 1
Prevention of Stroke in Survivors of Brain Bleeding with Atrial Fibrillatio
EUCTR2018-002176-41-GBImperial College London654
Active, not recruiting
Phase 1
Prevention of Stroke in Survivors of Brain Bleeding with Atrial FibrillatioIschaemic stroke prevention in patients with atrial fibrillation and previous intracerebral haemorrhageTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
EUCTR2018-002176-41-ESImperial College of Science, Technology and Medicine654
Active, not recruiting
Phase 1
Prevention of Stroke in Survivors of Brain Bleeding with Atrial FibrillatioIschaemic stroke prevention in patients with atrial fibrillation and previous intracerebral haemorrhageMedDRA version: 20.0Level: PTClassification code 10003658Term: Atrial fibrillationSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 21.1Level: LLTClassification code 10067816Term: Cardioembolic strokeSystem Organ Class: 100000004852MedDRA version: 20.1Level: LLTClassification code 10055815Term: Haemorrhage intracerebralSystem Organ Class: 100000004852Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
EUCTR2018-002176-41-FRImperial College of Science, Technology and Medicine654
Active, not recruiting
Phase 1
Prevention of Stroke in Survivors of Brain Bleeding with Atrial Fibrillatio
EUCTR2018-002176-41-ITImperial College of Science, Technology and Medicine654